Table 2 Active clinical trials targeting distinct pathways in Parkinson’s disease patients
From: Genotype-driven therapeutic developments in Parkinson’s disease
Trial name | Registration number | Study design | Outcomes | Study participants |
|---|---|---|---|---|
α-Synuclein aggregation | ||||
Impact of Bosutinib on safety, tolerability, biomarkers and clinical outcomes in dementia with lewy bodies | NCT03888222 | MonoC, DB, R, PC | 1st: Safety and tolerability | DLB patients |
Single ascending dose study of MEDI1341 in healthy volunteers | NCT03272165 | MultiC, DB, R, PC | 1st: Safety and tolerability | HVs |
Endosomal/lysosomal dysfunction | ||||
A study to evaluate the safety, tolerability, and pharmacokinetics of BIIB094 in adults with Parkinson's disease (REASON) | NCT03976349 | MultiC, DB, R, PC | 1st: Safety and tolerability | mPD (LRRK2), IPD patients |
A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL151 in healthy volunteers | NCT04557800 | MultiC, DB, R, PC | 1st: Safety and tolerability | HVs |
Study to evaluate DNL151 in subjects with Parkinson's disease | NCT04056689 | MultiC, DB, R, PC | 1st: Safety and tolerability | PD patients |
Study to evaluate DNL201 in subjects with Parkinson's disease | NCT03710707 | MultiC, DB, R, PC | 1st: Safety and tolerability | mPD (LRRK2), IPD patients |
Phase 1/2a clinical trial of PR001A in patients with Parkinson's disease with at least one GBA1 mutation (PROPEL) | NCT04127578 | MultiC, DB, R, PC | 1st: Safety and tolerability | mPD (GBA), IPD patients |
Ambroxol as a treatment for Parkinson's disease dementia | NCT02914366 | MonoC, DB, R, PC | 1st: ADAS-cog and ADCS-CGIC | PDD patients |
Mitochondrial dysfunction | ||||
Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease | NCT03840005 | MultiC, DB, R, PC | 1st: Safety and tolerability 2nd: various | IPD patients |
An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease | DRKS00015880 | MultiC, DB, R, PC | 1st: MDS-UPDRS-III 2nd: 31P-MRSI | mPD (Parkin and PINK1) and genetically stratified IPD patients |
Nicotinamide supplementation in early Parkinson's disease (NOPARK) | NCT03568968 | MultiC, DB, R, PC | 1st: MDS-UPDRS-III | Treatment naïve PD patients |
Metabolic Cofactor Supplementation in Alzheimer's disease (AD) and Parkinson's disease (PD) patients | NCT04044131 | MultiC, DB, R, PC | 1st: assessment of cognition, ADL, and MDS-UPDRS-III | IPD or AD patients |
The use of vitamin K2 in patients with Parkinson's disease and mitochondrial dysfunction (PD-K2) | DRKS00019932 | MonoC, DB, R, PC | 1st: 31P-MRSI 2nd: additional neuroimaging marker to assess mitochondrial dysfunction | mPD (Parkin and PINK1), IPD patients, and HVs |